Cancer

Title
The Study of Sorafenib and Chemotherapy in Individuals Who Have Liver Cancer (Hepatocellular Carcinoma) That is Not Removable by Surgery and the Cancer Has Not Spread Outside the Liver
Trial Number
203147011911
Number of Participants
400
Principal Investigator
Eligibility

Patients must be 18 years or older with a diagnosis of hepatocellular carcinoma by at least one of the following criterion: histologically confirmed, magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis and at least one solid liver lesion > 2 cm with early enhancement and delayed enhancement washout regardless of alpha-feto protein levels (AFP), or AFP > 400 ng/mL and evidence of at least one solid liver lesion > 2 cm regardless of specific imaging characteristics on CT or MRI.

Purpose

The purpose of this study is to see if adding the oral chemotherapy pill, sorafenib, to localized chemotherapy (chemoembolization) to the liver will help individuals to live longer than treatment with localized chemotherapy to the liver without sorafenib.

Enrollment

(708) 327-2831

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.